Contact this trialFirst, we need to learn more about you.
Protein Inhibitor
Pelcitoclax + Cobimetinib for Recurrent Ovarian and Endometrial Cancers
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial tests the safety and best dose of two drugs, pelcitoclax and cobimetinib, in patients with recurring ovarian and endometrial cancers. Pelcitoclax helps kill cancer cells, and cobimetinib slows their growth. The goal is to find an effective dose and observe how well the combination works in shrinking or stabilizing tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service